Increasing Applications in Molecular Diagnostics, Particularly in Cancer
Cancer diagnosis and treatment is currently undergoing a paradigm shift with the incorporation of RNAi techniques in personalized medicines and molecular diagnostics. The availability of high throughput techniques for the identification of altered cellular molecules and metabolites allows the use of RNAi techniques in various cancer diagnosis and targeting approaches. For diagnostics purposes, small interfering RNAs (siRNA) or microRNAs (miRNA) can be utilized, and commercial availability of siRNAs to silence virtually any gene in the human genome is dramatically accelerating the pace of molecular diagnosis and biomedical research. Increasing application of RNAi in molecular diagnosis and its viability as a therapeutic technique is expected to drive the growth of the RNAi market during the forecast period.
Additionally, improving synthetic delivery carriers and chemical modifications to RNA are also fuelling the growth of the global RNAi technology market.
Stringent FDA Regulations and Changing Reimbursement Environment
In the recent years, there has been a decline in the FDA drug approval rates. Getting FDA approval for a new drug has become extremely challenging. It had approved less than half the number of new drugs in 2016 (19 so far), when compared to 2015 (45 total) and 2014 (41 total). Hence, despite the large investments, there has been a decline in the number of innovative drugs manufactured. FDA explains manufacturing standards and other complying issues as major reasons for this declining trend. This can impede the growth of the RNAi therapeutics, especially since the miRNAs and siRNAs fall into the relatively new field of genetic medicine, wherein they may require more intensified clinical trials. The highly extensive clinical trials effectively result in low approval rates of drugs. This would mean that the stringent guidelines will be a major restraint for the growth of the market.
Additionally, the unstable and immunogenic nature of RNA is also restraining the growth of the global RNAi technology market.
North America Dominating the Market
North America, especially the United States, holds the largest market share of the RNAi market. There are a large number of companies and research institutes in the country with a huge amount being invested in research on drug discovery using RNAi technology; the recent technological and medical advances are available in North America. Other factors, such as growing population and high incidence of diseases, such as liver disorders and cancers, are fuelling the regional growth of this market.
Key Developments in the Market
- November 2017: Arcturus Therapeutics merged with Alcobra Ltd.
- October 2017: Alnylam and Vir Form Strategic alliance to advance RNAi Therapeutics for infectious diseases.
- October 2017: Arcturus Therapeutics announced strategic collaboration with Johnson & Johnson Innovation to discover and develop RNA medicines.
Reasons to Purchase the Report
- Current and future RNAi technology outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3-month analyst support, along with the Market Estimate sheet (in excel)
This report can be customized to meet your requirements. Please connect with our representative , who will ensure you get a report that suits your needs.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities And Challenges Analysis (DROC)
6.1 Market Driver
6.1.1 Increasing Number of Applications in Molecular Diagnostics, Particularly in Cancer
6.1.2 Improving synthetic delivery carriers and chemical modifications to RNA
6.2 Market Restraints
6.2.1 Stringent FDA Regulations and Changing Reimbursement Environment
6.2.2 Unstable Potentially Immunogenic Nature of RNA
6.4 Key Challenges
7. Market Segmentation
7.1 By Application
7.1.1 Drug Discovery & Development
188.8.131.52 Ocular Disorders
184.108.40.206 Respiratory Disorders
220.127.116.11 Hepatitis B and C
18.104.22.168 Autoimmune Hepatitis
22.214.171.124 Neurological Disorders
7.2 By Geography
7.2.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 Australia & New Zealand
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
7.2.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
7.2.5 South America
184.108.40.206 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Alnylam Pharmaceuticals
9.2 Quark Pharmaceuticals Inc.
9.3 Qiagen NV
9.4 Merck & Co. Inc. (Sigma Aldrich)
9.5 Thermo Fisher Scientific Inc.
9.6 Silence Therapeutics
9.7 Benitec Biopharma Ltd
9.8 Ionis Pharmaceuticals Inc.
9.9 Arcturus Therapeutics
9.10 Takara Bio Inc. (Clonetch)
9.11 Dharmacon (Horizon Discovery Group Company)
10. Future Outlook of the Market
- ALNYLAM PHARMACEUTICALS
- QUARK PHARMACEUTICALS INC.
- BENITEC BIOPHARMA LTD
- ISIS PHARMACEUTICALS
- RXI PHARMACEUTICALS
- FILMTEC CORPORATION
- SILENCE THERAPEUTICS
- MERCK (SIRNA)
- TEKMIRA PHARMACEUTICALS CORPORATION